2025
A Rare Case of Cyberlindnera jadinii Fungemia in a Kidney Transplant Recipient: A Case Report
Patil J, Sogawa H, Mulligan D. A Rare Case of Cyberlindnera jadinii Fungemia in a Kidney Transplant Recipient: A Case Report. Case Reports In Transplantation 2025, 2025 DOI: 10.1155/crit/3478928.Peer-Reviewed Original ResearchKidney transplant recipientsTransplant recipientsRare caseSolid organ transplant recipientsAspergillus speciesOrgan transplant recipientsAntifungal prophylaxisFungal infectionsCausative agentGraft rejectionPerioperative mortalityCase reportKidney transplantationCardiovascular eventsFungemiaEarly diagnosisQuality of lifeSpeciesKidneyImmunosuppressive pathologyMortalityRecipientsInfectionCandidaAspergillus
2024
C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via selective activation of monocyte subsets
Kiefer J, Zeller J, Schneider L, Thomé J, McFadyen J, Hoerbrand I, Lang F, Deiss E, Bogner B, Schaefer A, Chevalier N, Horner V, Kreuzaler S, Kneser U, Kauke-Navarro M, Braig D, Woollard K, Pomahac B, Peter K, Eisenhardt S. C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via selective activation of monocyte subsets. Journal Of Advanced Research 2024, 72: 401-420. PMID: 38992424, PMCID: PMC12147648, DOI: 10.1016/j.jare.2024.07.007.Peer-Reviewed Original ResearchAcute allograft rejectionC-reactive proteinVascularized Composite AllotransplantationAllograft rejectionAcute rejectionAllograft survivalGraft rejectionAttenuate acute allograft rejectionPreventing acute allograft rejectionImmune responseLong-term allograft survivalFacial Vascularized Composite AllotransplantationClinical allograft rejectionReduced allograft survivalChronic allograft rejectionIntravital imagingNon-classical monocytesMarkers of inflammationAcute-phase reactantsImmune-inflammatory reactionPro-inflammatory propertiesMononuclear phagocyte systemAcute-phase responseGraft infiltrationInnate immune responseImmunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes
Huelsboemer L, Boroumand S, Kochen A, Dony A, Moscarelli J, Hauc S, Stögner V, Formica R, Pomahac B, Kauke-Navarro M. Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes. Frontiers In Transplantation 2024, 3: 1366243. PMID: 38993787, PMCID: PMC11235358, DOI: 10.3389/frtra.2024.1366243.Peer-Reviewed Original ResearchCMV infectionImmunosuppressive regimensImmunosuppressive strategiesTransplant recipientsIncidence of rejection episodesClinical CMV infectionTriple maintenance therapyIncidence of rejectionEpisodes of rejectionIndividualized immunosuppressive regimensEffective immunosuppressive therapySystematic reviewFace transplant patientsHand transplant recipientsHand transplantationFacial graftImmunosuppressive therapyMaintenance therapyRejection episodesFacial mucosaGraft lossGraft rejectionTherapy regimensTransplant patientsRenal failure
2023
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies
Ji S, Liu H, Pachella L, Stephenson R, Groisberg R, Weiss S. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies. Frontiers In Transplantation 2023, 2: 1284740. PMID: 38993910, PMCID: PMC11235332, DOI: 10.3389/frtra.2023.1284740.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCutaneous squamous cell carcinomaObjective response rateMerkel cell carcinomaSolid organ transplant recipientsOrgan transplant recipientsSOT recipientsGraft rejectionCutaneous malignanciesCheckpoint inhibitorsTransplant recipientsCell carcinomaRetrospective analysisFirst-line immune checkpoint inhibitorsPrior systemic therapyAdvanced skin cancerSquamous cell carcinomaAdvanced cutaneous malignanciesImmunosuppressive therapyAllograft rejectionGraft failureSystemic therapyAdvanced melanomaCare therapyImmunosuppressive agentsCellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell typesRole of abatacept in the prevention of graft-versus-host disease: current perspectives
Ngwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances In Hematology 2023, 14: 20406207231152644. PMID: 36845849, PMCID: PMC9943961, DOI: 10.1177/20406207231152644.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantChronic GVHDGVHD prophylaxisDonor hematopoietic stem cell transplantSteroid-refractory chronic GVHDPrevention of graftSevere acute GVHDStem cell transplantAcute GVHDGVHD preventionHLA disparityHost diseaseGraft rejectionHSCT settingUnrelated donorsCalcineurin inhibitorsCell transplantNonmalignant disordersAlternative donorsMouse modelClinical practiceGVHDProphylaxisLimited reports
2022
RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice.
Joshi AA, Wu Y, Deng S, Preston-Hurlburt P, Forbes JM, Herold KC. RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice. Clinical Immunology 2022, 245: 109165. PMID: 36257528, DOI: 10.1016/j.clim.2022.109165.Peer-Reviewed Original ResearchConceptsXenograft rejectionIL-17AHumanized miceIL-1βT cellsImmune responseRAGE antagonistsAdaptive human immune responsesPD-1 expressionSkin graft rejectionHuman immune cell responsesImmune cell responsesHuman immune responseHuman immune cellsInnate immune responseAdvanced glycation endproductsInhibition of pathwaysSmall molecule antagonistsMultiple inflammatory processesAZ therapyRAGE antagonismGraft rejectionIL-23Serum levelsMedian timeImmunotolerance in liver transplantation: A primer for the clinician
Pérez-Escobar J, Jimenez J, Rodríguez-Aguilar E, Servín-Rojas M, Ruiz-Manriquez J, Safar-Boueri L, Carrillo-Maravilla E, Navasa M, García-Juárez I. Immunotolerance in liver transplantation: A primer for the clinician. Annals Of Hepatology 2022, 28: 100760. PMID: 36179797, DOI: 10.1016/j.aohep.2022.100760.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsTransplant recipientsDevelopment of graft rejectionPharmacological interventionsAssociated with increased mortalityImmunosuppression withdrawal trialSolid organ transplantationRisk of rejectionMechanisms of immunotolerancePotential pharmacological interventionsImmunotolerance inductionGraft dysfunctionGraft injuryGraft rejectionImmunosuppressive medicationsOncological complicationsWithdrawal trialLiver transplantationTissue biomarkersClinical studiesImmunotoleranceOrgan transplantationImmunosuppressionAntimicrobial responsesTransplantationImmune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatientsAlloantigen-specific Chimeric Antigen Receptor Regulatory T cell therapy in non-human primate islet transplantation
Ellis G, Coker K, Winn D, Deng M, Shukla D, Bhoj V, Milone M, Wang W, Liu C, Naji A, Duran-Struuck R, Riley J. Alloantigen-specific Chimeric Antigen Receptor Regulatory T cell therapy in non-human primate islet transplantation. The Journal Of Immunology 2022, 208: 175.21-175.21. DOI: 10.4049/jimmunol.208.supp.175.21.Peer-Reviewed Original ResearchCAR-TregsLarge animal modelPeripheral bloodIslet transplantationT cellsAnimal modelsRegulatory T cell therapyArtificial antigen presenting cellsCAR-Treg therapyEffector T cellsT-cell therapyAntigen presenting cellsOptimization of therapyType 1 diabetesCAR T cellsExpanded TregsTreg therapyAdoptive transferGraft rejectionAdoptive therapyDiabetic recipientsImmunosuppressive agentsNegative recipientsTreatment of cancerBlood glucoseT cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation
Borges T, Abarzua P, Gassen R, Kollar B, Lima-Filho M, Aoyama B, Gluhova D, Clark R, Islam S, Pomahac B, Murphy G, Lian C, Talbot S, Riella L. T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation. Cell Reports Medicine 2022, 3: 100559. PMID: 35492875, PMCID: PMC9040185, DOI: 10.1016/j.xcrm.2022.100559.Peer-Reviewed Original ResearchConceptsLimb transplantationTransplant recipientsSkin antigen-presenting cellsSolid organ transplant recipientsAccelerated graft rejectionOrgan transplant recipientsSkin transplantation modelAntigen-presenting cellsLife-changing procedureImmunosuppressive approachesTh17 cellsGraft rejectionGreater immunogenicityCell infiltrationSkin biopsiesTransplantation modelSkin xenograftsChemokine CCL18Immune moleculesTransplantationCCL18RecipientsMolecular characterizationChemokinesCCR8 receptor
2021
Shotgun Immunoproteomics for Identification of Nonhuman Leukocyte Antigens Associated With Cellular Dysfunction in Heart Transplant Rejection
Gates K, Panicker A, Biendarra-Tiegs S, Vetr N, Higuita M, Nelson T, Pereira N, Griffiths L. Shotgun Immunoproteomics for Identification of Nonhuman Leukocyte Antigens Associated With Cellular Dysfunction in Heart Transplant Rejection. Transplantation 2021, 106: 1376-1389. PMID: 34923540, DOI: 10.1097/tp.0000000000004012.Peer-Reviewed Original ResearchConceptsAntibody-mediated rejectionHeart transplant recipientsAntigen-specific responsesNon-HLAPrevalence antigensAcute rejectionTransplant recipientsAbsence of donor-specific anti-HLA antibodiesDonor-specific anti-HLA antibodiesNon-HLA antibody responsesAntibody-mediated rejection patientsNon-AMR patientsAnti-HLA antibodiesHeart transplant rejectionPatient immunoglobulin GHigh-prevalence antigenEndothelial cell functionEndomyocardial biopsyAllograft rejectionGraft rejectionHeart biopsiesTransplant rejectionAntibody responseImmunofluorescence stainingPatientsEtonogestrel contraceptive implant uptake and safety among solid organ transplant recipients
Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsReproductive-age womenEtonogestrel contraceptive implantContraceptive implant usersTransplant recipientsContraceptive implantsCommon transplant-related complicationPost-transplant infectionsSafe contraceptive optionTransplant-related outcomesRetrospective cohort studyTransplant-related complicationsGraft-related complicationsSide effect profileTertiary medical centerRisk of pregnancyImplant usersContraceptive implant useAdditional health risksPregnancy patternsCohort studyGraft complicationsGraft rejectionEffect profileImpact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant
Johnston JP, Cohen EA, Casal GH, Asch WS, Reardon DP. Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant. Journal Of Pharmacy Practice 2021, 35: 701-706. PMID: 33759619, DOI: 10.1177/08971900211000702.Peer-Reviewed Original ResearchConceptsLow-dose fluconazoleRenal transplant patientsAdverse drug reactionsTAC levelsTransplant patientsGraft rejectionDrug reactionsTherapeutic levelsSingle-center retrospective chart reviewPost-operative day 10Azole antifungal therapySubtherapeutic tacrolimus levelsTAC dose adjustmentRenal transplant recipientsTotal daily doseRetrospective chart reviewTacrolimus dosingTacrolimus levelsRenal transplantTransplant recipientsChart reviewSecondary outcomesDaily doseDose adjustmentPrimary outcome
2020
CTLA-4 rs231775 and risk of acute renal graft rejection: an updated meta-analysis with trial sequential analysis
Cargnin S, Galli U, Shin J, Terrazzino S. CTLA-4 rs231775 and risk of acute renal graft rejection: an updated meta-analysis with trial sequential analysis. Scientific Reports 2020, 10: 12850. PMID: 32732985, PMCID: PMC7393166, DOI: 10.1038/s41598-020-69849-4.Peer-Reviewed Original ResearchConceptsFalse positive report probabilityCTLA-4 rs231775Trial sequential analysisKidney transplant recipientsCTLA-4Odds ratioSystematic reviewAcute rejectionTransplant recipientsMeta-analysisAcute renal graft rejectionWeb of KnowledgeGenetic risk determinantRenal graft rejectionReport probabilityCumulative Z-curveMeta-analysesGraft rejectionCochrane LibraryComprehensive searchRenal transplantationRs231775Sequential analysisFutility boundaryRisk determinants
2018
Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection
Tahvildari M, Inomata T, Amouzegar A, Dana R. Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection. Current Ophthalmology Reports 2018, 6: 266-274. PMID: 31807370, PMCID: PMC6894425, DOI: 10.1007/s40135-018-0191-2.Peer-Reviewed Original ResearchCorneal transplantationAllograft survivalGraft rejectionT cellsActivation of effector T cellsIncreased risk of graft rejectionPromote corneal allograft survivalRegulatory T-cell modulationInduction of immune toleranceRisk of graft rejectionTherapeutic approachesCorneal allograft survivalExpansion of TregsCorneal graft rejectionEffector T cellsRegulatory T cellsPromote transplant survivalAdaptive immune responsesHigh-risk allograftsModulation of cytokinesHost bedTargeting TregsImmune toleranceGraft survivalTregsRegulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection
Lim S, Kirkiles-Smith NC, Pober JS, Bothwell ALM, Choi JM. Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection. Biomaterials 2018, 183: 128-138. PMID: 30165256, PMCID: PMC6141312, DOI: 10.1016/j.biomaterials.2018.08.049.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationCell-Penetrating PeptidesCTLA-4 AntigenCytokinesEndothelial CellsFemaleGraft RejectionHuman Umbilical Vein Endothelial CellsHumansLymphocyte ActivationMice, Inbred BALB CMice, KnockoutMice, SCIDMicrovesselsReceptors, ChemokineSkinSkin TransplantationT-LymphocytesConceptsT cell responsesHuman T cell responsesT cell infiltrationHuman T cellsT cellsCell responsesGraft rejectionCell infiltrationSCID/beige miceCell-permeable peptideBlood cytokine levelsT cell alloresponsesCD8 T cellsChemokine receptor expressionGranzyme B expressionAlloreactive T cellsSignificant side effectsDouble knockout miceHuman T cell activationBcl-2-transduced human umbilical vein endothelial cellsT cell activationHuman umbilical vein endothelial cellsUmbilical vein endothelial cellsSystemic immunosuppressantsAllograft rejection
2017
The critical role of SENP1-mediated GATA2 deSUMOylation in promoting endothelial activation in graft arteriosclerosis
Qiu C, Wang Y, Zhao H, Qin L, Shi Y, Zhu X, Song L, Zhou X, Chen J, Zhou H, Zhang H, Tellides G, Min W, Yu L. The critical role of SENP1-mediated GATA2 deSUMOylation in promoting endothelial activation in graft arteriosclerosis. Nature Communications 2017, 8: 15426. PMID: 28569748, PMCID: PMC5461500, DOI: 10.1038/ncomms15426.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArteriosclerosisCysteine EndopeptidasesDisease ProgressionDNAEndopeptidasesEndothelial CellsEndothelium, VascularGATA2 Transcription FactorHuman Umbilical Vein Endothelial CellsHumansInflammation MediatorsLeukocytesMaleMice, Inbred C57BLMice, KnockoutModels, BiologicalProtein BindingProtein StabilitySumoylationConceptsGraft arteriosclerosisEndothelial activationClinical graft rejectionConsequent endothelial dysfunctionNF-κB activityRole of SENP1Post-translational SUMOylationAllograft failureEndothelial dysfunctionGraft rejectionGraft endotheliumLeukocyte recruitmentVascular remodellingCardiovascular disordersNeointima formationNF-κBClinical researchDiminished inductionEndothelial cellsMajor causeAdhesion moleculesPotential involvementInflammationArteriosclerosisSENP1
2016
High Endothelial Venules and Lymphatic Vessels in Tertiary Lymphoid Organs: Characteristics, Functions, and Regulation
Ruddle NH. High Endothelial Venules and Lymphatic Vessels in Tertiary Lymphoid Organs: Characteristics, Functions, and Regulation. Frontiers In Immunology 2016, 7: 491. PMID: 27881983, PMCID: PMC5101196, DOI: 10.3389/fimmu.2016.00491.Peer-Reviewed Original ResearchTertiary lymphoid organsHigh endothelial venulesSecondary lymphoid organsLymph nodesAntigen-presenting cellsLymphoid organsEndothelial venulesLymphatic vesselsStromal cellsCentral memory cellsPrimary lymphoid organsTransport antigensGraft rejectionEffector cellsChemokine expressionChronic inflammationPeyer's patchesAntigen presentationInflammatory signalsB cellsBone marrowImmune systemReticular cellsMicrobial infectionsCellular compositionThe Critical Role of SENP1‐Mediated GATA2 DeSUMOylation in Graft Arteriosclerosis by Promoting Endothelial Activation
Qiu C, Wang Y, Zhu X, Song L, Zhang H, Qin L, Tellides G, Min W, Yu L. The Critical Role of SENP1‐Mediated GATA2 DeSUMOylation in Graft Arteriosclerosis by Promoting Endothelial Activation. The FASEB Journal 2016, 30 DOI: 10.1096/fasebj.30.1_supplement.165.3.Peer-Reviewed Original ResearchGraft arteriosclerosisEndothelial adhesion moleculesEC activationEndothelial activationAdhesion moleculesGA progressionNeointima formationClinical graft rejectionAorta transplantation modelEndothelial cell activationLeukocyte-endothelial adhesionConditional knockout miceDeficient graftsGraft failureGraft rejectionVasomotor dysfunctionEndothelial overexpressionEndothelial inflammationAllograft transplantationVascular occlusionEC dysfunctionTransplantation modelLeukocyte recruitmentVascular remodelingKnockout mice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply